Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264120 | 0.99 | MMP2 (0.48) | MMP2MMP12FFAR1FFAR4MGLL | |
| SCHEMBL20556334 | 0.89 | KDM4E (0.39) | MMP2MMP12 | |
| SCHEMBL20556393 | 0.87 | FFAR1 (0.48) | MMP2MMP12FFAR1FFAR4 | |
| SCHEMBL181321 | 0.81 | MMP2 (0.52) | MMP2MMP12FFAR1FFAR4MGLL | |
| SCHEMBL181334 | 0.80 | FFAR1 (0.44) | MMP2MMP12FFAR1FFAR4 | |
| SCHEMBL7330109 | 0.80 | MMP2 (0.50) | MMP2MMP12FFAR1FFAR4MGLL | |
| SCHEMBL2402609 | 0.79 | MMP2 (0.59) | MMP2MMP12FFAR1FFAR4MGLL | |
| SCHEMBL10412413 | 0.77 | KDM4E (0.45) | — | |
| SCHEMBL23588023 | 0.76 | ACACB (0.49) | MMP2MMP12FFAR1FFAR4 | |
| SCHEMBL15008913 | 0.76 | ACACB (0.49) | MMP2MMP12FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661084-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3145944-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| EP-3033352-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179441-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | MMP2 241/4885MMP12 452/4885FFAR1 3836/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | MMP2 295/4885MMP12 802/4885FFAR1 4119/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MMP2 295/4885MMP12 802/4885FFAR1 4119/4885 |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | ANPEP, NPEPPS, PEPD | MMP2 175/4885MMP12 274/4885FFAR1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.